RT Journal Article
SR Electronic
T1 Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4361
OP 4366
DO 10.21873/anticanres.12737
VO 38
IS 7
A1 SHUICHI IZUMOTO
A1 MASAHARU MIYAUCHI
A1 TAKAYUKI TASAKI
A1 TAKESHI OKUDA
A1 NOBUHIRO NAKAGAWA
A1 NAOKI NAKANO
A1 AMAMI KATO
A1 MITSUGU FUJITA
YR 2018
UL http://ar.iiarjournals.org/content/38/7/4361.abstract
AB Background/Aim: Excessive extracellular glutamate activates AMPA-type glutamate receptors (AMPA receptors) and induces seizures. Antagonistic activation of AMPA receptors inhibits epilepsy and glioma growth in in vitro and in vivo studies. This study was conducted to evaluate the clinical impacts of perampanel (PER), a novel AMPA receptor antagonist, on seizures and tumor progression in glioma patients with uncontrollable epilepsy. Patients and Methods: Twelve glioma patients with uncontrollable epilepsy were treated with PER. Seizure response, PER concentration, and tumor volume were assessed. Results: Obvious seizure control was observed in 10 analyzed patients (100%) and 6 patients (60%) became seizure-free. Median plasma concentrations of PER were 296 ng/ml in those with 4 mg/day PER treatment and 518 ng/ml in those with 8 mg/day PER treatment. High-intensity lesions in fluid-attenuated inversion recovery of magnetic resonance imaging (MRI) were volumetrically assessed to analyze tumor size. Volume reduction was detected within 6 months in correlation with increased plasma levels of PER. Conclusion: PER treatment was effective in uncontrollable epilepsy with gliomas. MRI images showed the inhibition of tumor growth.